To evaluate the efficacy and safety of esomeprazole-based triple therapy compared with lansoprazole therapy as first-line eradication therapy for patients with Helicobacter pylori ( H. pylori ) in usual post-marketing use in Japan , where the clarithromycin ( CAM ) resistance rate is @ % .